Servier has become the first company to get US approval for an IDH inhibitor as a treatment for myelodysplastic syndromes (MDS) after its Tibsovo drug was cleared by the FDA for the blood cancer.
Servier could become the first company to bring an IDH inhibitor to market in the US for patients with myelodysplastic syndromes (MDS) next year, after the FDA started a priority review of its Tibsovo ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results